Vivus’ Qsiva Down But Not Out At EMA; Lundbeck Will Write Off Acrescent
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus’ decision to fight CHMP rejection of Qsiva is a worthy cause, but Lundbeck confirms that Acrescent’s not unexpected elimination is the end of the line for the Alzheimer’s drug combination.
You may also be interested in...
To Market Qsymia, Vivus Takes On Additional Debt
Sales of the weight-loss drug haven’t been brisk, but Vivus can fortify its balance sheet with up to $110 million in debt. Analysts say it could raise more soon, provided it gains a regulatory victory.
EMA’s CHMP Sets Back Vivus’ Qsiva For At Least Two Years In Europe
The EMA has rejected Vivus’ Qsiva for obesity for the second time, citing potential long-term health issues and probably delaying the product’s European launch for at least two years.